Search Results - "Majumder, Indrani"

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission

    Phase II consolidation trial with anti-Lewis-Y monoclonal antibody (hu3S193) in platinum-sensitive ovarian cancer after a second remission by Smaletz, Oren, Ismael, Gustavo, Del Pilar Estevez-Diz, Maria, Nascimento, Ivana L O, de Morais, Ana Luiza Gomes, Cunha-Junior, Geraldo Felício, Azevedo, Sergio J, Alves, Venancio A, Moro, Ana Maria, Yeda, Fernanda P, Dos Santos, Mariana Lopes, Majumder, Indrani, Hoffman, Eric W

    “…To investigate the efficacy and safety of hu3S193, a humanized anti-Lewis-Y monoclonal antibody, as a consolidation strategy in patients with…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  2. 2
    Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR)

    Anti-LeY monoclonal antibody (mAb) hu3S193 as consolidation therapy for patients (pts) with relapsing platinum sensitive ovarian cancer (OC) after achieving a second complete response (2CR) by Smaletz, Oren, Ismael, Gustavo, Estevez-Diz, Maria Del Pilar, Nascimento, Ivana Lucia Oliveira, Wiermann, Ana Luiza Gomes de Morais, Cunha, Geraldo Felicio, Azevedo, Sergio J, Alves, Venâncio A, Moro, Ana M, Yeda, Fernanda Perez, dos Santos, Mariana Lopes, Majumder, Indrani, Hoffman, Eric W.

    Published in Journal of clinical oncology (20-05-2017)
    “…Abstract only e17039 Background: Lewis-Y (LeY) antigen is a blood group related antigen expressed in 75% of OC. hu3S193 is a humanized anti-LeY IgG1 mAb with…”
    Get full text
    Journal Article
    Save to List
    Saved in:

Search Tools: